Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group

Abstract

Children treated for childhood malignancies may be at risk for early or delayed onset hearing loss that can impact learning, communication, school performance, social interaction, and overall quality of life (QOL). Survivors at particular risk include those treated with platinum compounds (cis-and/or carboplatin) for neuroblastoma, hepatoblastoma, osteosarcoma, or germ cell tumors and/or those treated with radiation impacting the ear at doses greater than 30 Gray (Gy) for pediatric head and neck tumors. The aims of the Auditory/Hearing Late Effects Task Force of Children’s Oncology Group in this report were: 1) to review ototoxicity resulting from childhood cancer therapy including platinum compounds (cisplatin and carboplatin) and radiation; 2) to describe briefly cochlear pathophysiology and genetics of cisplatin-related hearing loss; 3) to explain the impact of hearing loss resulting from chemotherapy and radiation; and 4) to offer recommendations regarding evaluation and management of pediatric patients at risk for treatment-related hearing loss. A questionnaire is included as a tool to assist pediatricians in assessment.

Head and Neck Cancer Patients’ Quality of Life

“…In child HNC, ototoxicity or RT affects the auditory apparatus. According to Grewal et al, adequate diagnosis and pharmacological agents could prevent or reduce ototoxicity in children [51]. Hearing loss in adults is related to HNC and different operative techniques can be used.…”

Late effects in children who underwent hematopoietic stem cell transplantation (review)

“…Так, в ПТП мо-гут страдать функции, связанные с дефектом органов чувств [83]. Наиболее часто встречаются катаракта, синдром сухого глаза и сенсорная тугоухость [84,85]. До четверти пациентов после трансплантации могут развивать помутнение задней капсулы хрусталика, ко-торое тем не менее не приводят к потере зрения.…”

Clinical trials in pediatric neuro-oncology: what is missing and how we can improve

“…Specifically, platinum-based chemotherapeutic agents and vinca alkaloids are associated with peripheral neuropathy that can persist for years after treatment [60]. Platinum-based agents can also lead to ototoxicity and hearing loss, putting children at risk for reduced learning, speech delay and decreased socioeconomic potential [61]. Compared with sibling controls, survivors of cancer have also shown increased risk for cataracts, glaucoma, legal blindness, double vision and dry eyes [62].…”